SEC Form 4 · accession 0001144204-15-019392
NAVIDEA BIOPHARMACEUTICALS, INC. · NAVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederick O Cope
Officer — Senior VP and CSO
Period of report
Mar 26, 2015
Accepted (ET)
Mar 30, 2015 · 4:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000810509
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.65 | Mar 26, 2015 | A | 162,000 | A | — | Mar 26, 2025 | Common Stock | 162,000 | 162,000 | D |
Explanation of responses
- F1Option vests 25% per year beginning on the first anniversary of the date of grant.